NCT04583553 2024-10-15
VS-UrineID
University of Kansas Medical Center
Withdrawn
Clinical Trials
28 trialsNCT05846165 2024-10-08
ISABELLA
University of Aberdeen
Phase NA Withdrawn
NCT05655598 2024-09-19
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Brown University
Phase 1 Withdrawn
NCT06301308 2024-04-24
A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
Second Xiangya Hospital of Central South University
Phase 3 Withdrawn
NCT03909893 2024-03-19
ARTGU
University Health Network, Toronto
Phase NA Withdrawn
NCT05335707 2024-02-28
Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
University of Kansas Medical Center
Withdrawn
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT05120622 2023-10-31
Rideau
University of British Columbia
Phase 1/2 Withdrawn
NCT03552796 2023-06-26
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer
University of Southern California
Phase 1 Withdrawn
NCT04127318 2022-09-23
Low-moderate Intensity Pedaling During Immunotherapy Administration
Rush University Medical Center
Phase NA Withdrawn
NCT04972253 2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT03839472 2022-05-11
Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT05260788 2022-04-14
Mapping 3D Bladder
University Health Network, Toronto
Withdrawn
NCT04073160 2020-07-07
TRIO Bladder
Duke University
Phase 1 Withdrawn
NCT04040725 2019-12-17
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT00880854 2019-11-15
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
University of Wisconsin, Madison
Phase 1 Withdrawn
NCT03298958 2019-06-12
Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 3 Withdrawn
NCT01060319 2019-04-18
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
Stanford University
Withdrawn
NCT02438852 2019-04-16
Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer
University of Southern California
Phase 3 Withdrawn
NCT01826097 2018-02-01
Improving Sensitivity of Urine Cytology for Bladder Cancer
Johns Hopkins University
Phase NA Withdrawn
NCT03007771 2017-10-06
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
Washington University School of Medicine
Phase 1 Withdrawn
NCT02252393 2016-11-09
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT00041171 2016-07-12
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Withdrawn
NCT01688414 2014-07-29
Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer
Stanford University
Phase NA Withdrawn
NCT01907308 2014-04-29
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Phase 2 Withdrawn
NCT00014287 2013-12-19
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
University of Pittsburgh
Phase 1 Withdrawn
NCT00084578 2013-07-15
Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder
Fox Chase Cancer Center
Phase NA Withdrawn
NCT01700010 2013-01-17
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn